OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals February 4, 2025
New Real-World DOR Data for JELMYTO Reports 68% RFS at Three Years in Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) January 28, 2025
NDA initiated with US FDA for TAR-200 for patients with BCG-unresponsive high-risk NMIBC January 21, 2025
Sasanlimab in Combination with BCG Improves EFS in Patients with BCG-Naïve, High-Risk NMIBC January 15, 2025
CAN-2409 Achieved Primary Endpoint in Ph 3 Prostate Cancer Trial, Showing Significantly Improved DFS December 18, 2024
Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of VHL Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced RCC December 18, 2024
Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive NMIBC December 10, 2024
Doses Selected for Ph 1b Expansion Trials Supported by Efficacy & Safety Profile Observed in Ph 1a Dose Escalation for JANX007 in metastatic CRPC December 10, 2024
Long-Term Follow-up Study to the OLYMPUS Trial Reports Median Duration of Response of 4 Years in Patients Who Achieved a Complete Response with JELMYTO® December 10, 2024
Positive Results Announced from Ph 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC December 10, 2024
Imfinzi granted Priority Review in the US for patients with muscle-invasive bladder cancer December 10, 2024
New Data from the OLYMPUS Trial Show mDOR of Four Years in Patients Who Achieved a Complete Response with JELMYTO December 4, 2024
Cancer Targeted Technology Receives Fast Track $2.4M Grant to Develop an Innovative PSMA-Targeted Small Molecule Drug Conjugate for Prostate Cancer November 26, 2024
FDA Accepts Supplemental NDA for NUBEQA® (darolutamide) for the Treatment of Patients with Metastatic HSPC November 26, 2024
Truqap combination in PTEN-deficient mHSPC demonstrated statistically significant and clinically meaningful improvement in rPFS in CAPItello-281 Ph 3 trial November 26, 2024
ECLIPSE Trial Meets Primary Endpoint, Showing a Statistically Significant & Clinically Meaningful Benefit for Patients With PSMA+ve metastatic CRPC November 19, 2024
MHRA grants marketing authorisation for BALVERSA (erdafitinib) for PD-(L)1 inhibitor-treated adults with unresectable/metastatic urothelial carcinoma (UC) with FGFR3 alterations November 12, 2024
FDA Regenerative Medicine Advanced Therapy (RMAT) Designation granted to ALLO-316 for Adult Patients with Advanced or Metastatic RCC November 5, 2024
Ph 2 Study of Masofaniten + Enzalutamide in metastatic CRPC Patients terminated; efficacy signals observed will not achieve target product profile November 5, 2024
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture October 29, 2024
